SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

The pharmacokinetics of this compound are similar in study subjects with diabetes and in those without. Age, gender, body weight, race, administration with food, or mild renal impairment do not ...

In 2020, the FDA issued guidance that patients taking an SGLT2 inhibitor -- including canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), ertugliflozin (Steglatro), and ...

The following is a summary of “Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial,” published in the February 2025 issue of Nephrology Dialysis ...

SGLT2 inhibitors are a new family of agents ... are genital mycotic and urinary tract infections. Dapagliflozin and canagliflozin are the first agents of this class, approved from the European ...

Although low-dose dapagliflozin was less effective in preventing hospitalization for heart failure, SGLT-2 inhibitors had similar cardiovascular outcomes in T2D. Canagliflozin and dapagliflozin ...

[Dharia A, et al. Annu Rev Med. 2023;1a] Five SGLT2 inhibitors ― canagliflozin (Invokana, Janssen), dapagliflozin (Farxiga, AstraZeneca), empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly ...

Lexicon Pharmaceuticals has reported that LX4211, an inhibitor of the sodium-dependent glucose transporter 2 (SGLT2; also known as SLC5A2), significantly improved glycaemic control in a Phase II ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.